用dupilumab成功治疗海利-海利病
Jake Breimann1, Saira N Agarwala1, Shayan Waseh1
1Dermatology, Temple University Hospital, Philadelphia, USA.
Cureus
|July 28, 2025
概括
海利-海利病 (HHD) 是一种罕见的遗传性皮肤疾病. 杜皮卢马布 (Dupilumab) 是一种IL-4/IL-13抑制剂,在治疗耐火性HD病例方面表现有前途,可显著缓解症状.
科学领域:
- 皮肤病学 皮肤病学
- 遗传学 遗传学 是一个
- 免疫学 免疫学 免疫学
背景情况:
- 海利-海利病 (HHD) 是一种罕见的自体主导性基因皮肤病.
- 它源于ATP2C1基因突变,破坏的平衡,并导致表皮性acantholysis.
- HHD呈现为三角形间区域的反复,痛苦的侵蚀,通常对标准治疗有抗性.
研究的目的:
- 报告一个耐火的海利-海利病病例.
- 为了评估dupilumab在患有严重的,耐治疗的HHD的患者中的疗效.
主要方法:
- 一名67岁的女性患有耐火性HHD,接受了dupilumab治疗.
- 患者患有持续的疼痛,性侵蚀,尽管先前的治疗包括局部皮质类固醇和口服视网类药物.
主要成果:
- 杜皮卢马布治疗在两个月内导致显著的症状改善.
- 患者在受影响区域的痛苦和性侵蚀中获得了缓解.
结论:
- 杜皮卢马布是一种IL-4/IL-13抑制剂,代表了海利-海利病的潜在治疗选择.
- 需要进一步的研究来确定dupilumab在HHD治疗中的长期疗效和安全性.
相关概念视频
Myasthenia Gravis: Overview and Treatment
3.6K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.6K
Drugs for Treatment of Diarrhea-Predominant IBS
993
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
993
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
863
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
863


